ResearcherUniversity of PisaActive in the last 2 years
Giulia Lencioni
Matched on ORCID iD 0009-0008-6521-337X; OpenAlex author ID A5083873656. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers
Papers 8
- CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218851↗
- Fluid shear stress enhances pancreatic cancer motility through YAP activation. First author DOI 10.1186/s13148-026-02163-4↗
- Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models. Co-author DOI 10.1016/j.semcancer.2024.12.003↗
- Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/biom15071018↗
- New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/md23080327↗
- Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. First author DOI 10.1002/ijc.35046↗
- Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Co-author DOI 10.1016/j.semcancer.2024.09.002↗
- Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. First author DOI 10.1136/jmg-2022-108910↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa Giovannetti · 5 shared papers, 2024–2026 · strength 1.40
- Paper Fluid shear stress enhances pancreatic cancer motility through YAP activation. DOI 10.1186/s13148-026-02163-4↗
- Paper CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer. DOI 10.1016/j.canlet.2026.218851↗
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Dongmei Deng · 2 shared papers, 2025–2026 · strength 0.61
- Juan Deng · 1 shared paper, 2026 · strength 0.36
- Adam Enver Frampton · 1 shared paper, 2026 · strength 0.36
- Liam Andrew McDonnell · 1 shared paper, 2026 · strength 0.33
- Mafalda Angelica Rocco · 1 shared paper, 2026 · strength 0.33
- Seçil Ak Aksoy · 1 shared paper, 2025 · strength 0.28
- Didem Karakaş · 1 shared paper, 2025 · strength 0.28
- Jelena Grahovac · 1 shared paper, 2025 · strength 0.28
- Sıla Sığırlı · 1 shared paper, 2025 · strength 0.28
- Maarten F. Bijlsma · 1 shared paper, 2025 · strength 0.28
- Julie Earl · 1 shared paper, 2025 · strength 0.28
- Mahrou Vahabi · 1 shared paper, 2025 · strength 0.27
- Daniela Carbone · 1 shared paper, 2025 · strength 0.27
- Camilla Pecoraro · 1 shared paper, 2025 · strength 0.27
- Barbara Parrino · 1 shared paper, 2025 · strength 0.27
- Patrizia Diana · 1 shared paper, 2025 · strength 0.27
- Geng Xu · 1 shared paper, 2025 · strength 0.26
- Luca Morelli · 1 shared paper, 2025 · strength 0.26
- Benoît Immordino · 1 shared paper, 2024 · strength 0.19
- Macarena Perán · 1 shared paper, 2024 · strength 0.19
- Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
- Naomi Walsh · 1 shared paper, 2024 · strength 0.19
- Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
- Rita Rebelo · 1 shared paper, 2024 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.